Retatrutide and trizepatide constitute a novel class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor https://iwanjany922453.blog4youth.com/profile